<- Go Home

CombiMatrix Corporation

CombiMatrix Corporation provides clinical molecular diagnostic laboratory services in the United States. The company focuses on pre-implantation genetic screening, prenatal diagnosis, miscarriage analysis, and pediatric developmental disorders. It provides molecular diagnostic services primarily in the areas of reproductive health for the diagnosis of developmental disorders associated with intellectual disability, congenital anomalies, dysmorphic features, and autism spectrum disorders. The company’s testing focuses on advanced technologies, including single nucleotide polymorphism, chromosomal microarray analysis, sequencing, fluorescent in situ hybridization, and high resolution karyotyping. It serves commercial insurance companies, healthcare institutions, government payors, and individuals. CombiMatrix Corporation was founded in 1995 and is headquartered in Irvine, California. As of November 14, 2017, CombiMatrix Corporation operates as a subsidiary of Invitae Corporation

Market Cap

$18.4M

Volume

162.9K

Cash and Equivalents

$2.4M

EBITDA

-$1.1M

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

$9.4M

Profit Margin

60.12%

52 Week High

$8.20

52 Week Low

$2.20

Dividend

N/A

Price / Book Value

3.48

Price / Earnings

-8.49

Price / Tangible Book Value

3.48

Enterprise Value

N/A

Enterprise Value / EBITDA

N/A

Operating Income

-$1.3M

Return on Equity

33.68%

Return on Assets

-10.12

Cash and Short Term Investments

$2.4M

Debt

$185.0K

Equity

$5.3M

Revenue

$15.6M

Unlevered FCF

-$371.3K

Sector

Life Sciences Tools and Services

Category

N/A

Hedge Funds that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Yellowbrick Portfolios that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Company Stock Pitches